Clinical trials: Mpox (Monkeypox)
Monkeypox, MPOX
Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)
The study is a prospective cohort that evaluates the clinical and immune-metabolic variables that may be linked to the risk and severity of the infection or even hospitalization or death in patients infected with the Mpox virus…
- Trial name
- NCT05784038
- Testing
- Viral genomic, Untargeted Metabolomics
- Where
- 3 sites in Brazil
- Volunteers
- 80 people
- Sponsor
- Hospital Israelita Albert Einstein
Monkeypox
Tecovirimat in Non-hospitalized Patients With Monkeypox
PLATINUM-CAN is a parallel collaborative trial linked with the sister trial PLATINUM led by Oxford University. PLATINUM-CAN is a multi-centre, randomized, placebo-controlled trial of Tecovirimat in non-hospitalized patients with…
- Trial name
- PLATINUM-CAN (NCT05534165)
- Testing
- Tecovirimat
- Where
- 3 sites in Canada
- Volunteers
- 120 people
- Sponsor
- Marina Klein
Monkeypox
Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine
This study is to evaluate the long-term immunogenicity of a boost dose of MVA-BN vaccine
- Trial name
- M-BOOST-FR (NCT06885853)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Monkey Pox
Performance Evaluation of Mpox Molecular POC Diagnostics
PP016 is a FIND-sponsored retrospective clinical performance study evaluating rapid molecular point-of-care (mPOC) tests for the detection of Mpox virus (MPXV) using archived lesion swab specimens collected in Uganda.
- Trial name
- NCT07620600
- Testing
- MPOX IVD test
- Where
- Uganda
- Volunteers
- 80 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Monkeypox
Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study
This observational study has been designed to characterize humoral and cellular immune responses after vaccination against monkeypox (MKP) in HIV positive and negative individuals at high risk of MKP infection during the…
- Trial name
- NCT05562323
- Where
- 3 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Monkeypox
A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
This study is a Phase 2 open-label, non-placebo controlled, multi-site clinical trial that will evaluate the standard SC regimen in adolescents ages 12 through 17 years, inclusive, and compared to the standard subcutaneous…
- Trial name
- NCT05740982
- Testing
- JYNNEOS
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
MPOX
Study of Tecovirimat for Human Mpox Virus
The purpose of this study was to see if tecovirimat is safe and successful at treating mpox. The main questions were whether tecovirimat reduced time to lesion resolution and pain compared to placebo (no treatment).
- Trial name
- STOMP (NCT05534984)
- Testing
- Tecovirimat Oral Capsule, Tecovirimat Oral Capsule (Open Label)
- Where
- 54 sites in United States, Argentina and 4 more
- Volunteers
- 719 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Monkeypox
Cohort Study of Healthcare Workers Receiving Imvanex®
During an outbreak of monkeypox in the UK in 2018, a third generation smallpox vaccine, Imvanex, was used for the first time to immunise healthcare workers who had been, or were expected to be, in contact with cases of monkeypox.
- Trial name
- NCT03745131
- Testing
- Blood draw
- Where
- 5 sites in United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Public Health England
Monkeypox (Mpox)
Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo
To evaluate the safety and immunogenicity of the MVA-SIBP vaccine using a double-blind, randomized, controlled, age de-escalation design conducted in Kinshasa, Democratic Republic of the Congo (DRC).
- Trial name
- NCT07253675
- Testing
- MVA-SIBP low dose, MVA-SIBP high dose, MVA-BN
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Mpox (Monkeypox)
Mpox Biology, Outcome, Transmission and Epidemiology
The MBOTE-Kamituga clinical and virological characterization protocol is a prospective observational cohort study with clinical and virological description of suspected mpox cases and longitudinal follow-up of confirmed mpox…
- Trial name
- NCT06652646
- Where
- Democratic Republic of the Congo
- Volunteers
- 1,000 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Monkey Pox, HIV Infections
Seroprevalence of Monkeypox Infection Among People Living With HIV and PrEP Users
This is a cohort, non-health product, non-interventional biomedical research, multi-centric, to determine the seroprevalence of mpox infection in the population of people living with HIV and in PrEP users in Ile-de-France and in…
- Trial name
- MonVIP (NCT05922735)
- Testing
- Questionnaire
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Mpox (Monkeypox), Monkeypox Virus Infection
DiagRaMIE Mpox Virus-RDC for the Diagnostic of Monkeypox
Monkeypox, caused by a virus in the Orthopoxvirus genus, is a zoonotic disease first identified in 1970 in the Democratic Republic of Congo (DRC).
- Trial name
- DiagRaMIE Mpox (NCT06840197)
- Testing
- NG-TestⓇ Monkeypox virus kit
- Where
- 3 sites in Republic of the Congo
- Volunteers
- 197 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Monkeypox
Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk
The goal of this observational study is to describe possible physical and psychological sequelae after an mpox infection and to evaluate the longevity of B- and T-cell immune responses in former mpox patients and vaccine…
- Trial name
- POQS-FU PLUS (NCT05879965)
- Where
- Belgium
- Volunteers
- 345 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Monkeypox
European Trial Into Mpox Infection
The goal of this randomized controlled double-blind clinical trial is to test the drug tecovirimat in patients with mpox (previously known as monkeypox) disease.
- Trial name
- EPOXI (NCT06156566)
- Testing
- Tecovirimat Oral Capsule
- Where
- 12 sites in Belgium, France and 6 more
- Volunteers
- 150 people
- Sponsor
- Miquel Ekkelenkamp
Monkey Pox
Clinical and Biological Aspects of the MONKEYPOX Disease
Monkey pox virus (MPXV), of the genus Orthopoxvirus, regularly causes epidemics in endemic areas of central and western Africa. Since January 1, 2022, cases of Monkey pox have been reported to WHO by 96 Member States in the 6 WHO…
- Trial name
- PoxVac22 (NCT05627713)
- Testing
- Blood sample collection, urine sample collection
- Where
- France
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Mpox (Monkeypox)
Investigating MPXV Viral Clearance in Mpox Cases and Secondary Attack Rate in Contacts
The MOVIE-TRACE project includes two complementary observational studies designed to improve the understanding of Mpox virus infection and its transmission within affected communities.
- Trial name
- MOVIE-TRACE (NCT07267390)
- Where
- Democratic Republic of the Congo
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Smallpox, Monkeypox
Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years
The Aim: To study safety, tolerability and pharmacokinetics of NIOCH-14 when administered orally using a set of clinical and laboratory-instrumental methods.
- Conditions
- Smallpox, Monkeypox, Cowpox, Vaccinia Virus Infection
- Trial name
- NCT05976100
- Testing
- NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally, NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 once orally. (Total 600 mg NIOCH-14 per day), NIOCH-14, 200 mg capsule: 6 capsules (200 mg each) of NIOCH-14 per day orally. (Total 1200 mg NIOCH-14 per day)
- Where
- Russia
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
Monkeypox
Tecovirimat for Treatment of Monkeypox Virus
The purpose of this study is to find out if tecovirimat is a safe and effective drug to treat monkeypox (mpox) in combination with standard of care (SOC).
- Trial name
- NCT05559099
- Testing
- Tecovirimat Oral Capsule
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 597 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Monkeypox
Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
This study is a Phase 2 randomized, open-label, non-placebo controlled, multi-site clinical trial that will evaluate two intradermal (ID) regimens for Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine compared to the…
- Trial name
- NCT05512949
- Testing
- JYNNEOS
- Where
- 8 sites in United States
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Smallpox, Monkeypox
Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years
The Aim: Study immunogenicity, confirm the safety and tolerability of different schedules of vaccination with "live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus"…
- Conditions
- Smallpox, Monkeypox, Cowpox, Vaccinia Virus Infection
- Trial name
- NCT05846243
- Testing
- VAC∆6 vaccine (10⁷ PFU), VAC∆6 vaccine (10⁶ PFU), Live Smallpox Vaccine
- Where
- 2 sites in Russia
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"